SAM #6912710440008

VA emergency bridge award for Pluvicto and Lutathera radiopharmaceuticals

The Department of Veterans Affairs awarded a one-month emergency bridge order for Pluvicto and Lutathera to support cancer care at the VA Greater Los Angeles Healthcare System. - Government buyer: Department of Veterans Affairs (VA), VA Greater Los Angeles Healthcare System, Network Contracting Office 22. - Awarded vendor and OEM: Novartis Pharmaceuticals Corporation, the manufacturer of both requested radiopharmaceuticals. - Products: Pluvicto and Lutathera; quantities, part numbers, and per-injection prices are not stated. - Purpose and requirements: Maintain continuity of patient cancer care while the VA finalizes its longer-term FY 2027 order. The justification cites urgent patient-care needs and the medications’ specialized, proprietary nature; Novartis is identified as the only authorized source listed in the VA NAC catalog. - Award amount: $769,496.80. - Performance period: One-month bridge order; no option period or annual subscription is stated.

View original listing